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Abstract
Background: Dopamine transporter based imaging has high diagnostic performance in distinguishing patients
with Parkinson’s disease (PD) from patients with non-Parkinsonian syndromes. Our previous study indicated that the
“Sniffin’ Sticks” odor identification test (SS-16) acts as a valid instrument for olfactory assessment in Chinese PD
patients. The aim of the study was to compare the efficacy of the two methods in diagnosing PD.
Methods: Fifty-two PD patients were involved in this study and underwent single photon emission computed
tomography (SPECT) imaging using the labeled dopamine transporter radiotracer 99mTc-TRODAT-1 to assess
nigrostriatal dopaminergic function. Olfactory function was assessed with the “Sniffin’ Sticks” odor identification test
(SS-16) in all patients who received DAT-SPECT scanning. Statistical analysis (SPSS version 21) was carried out to
determine the diagnostic accuracy of SS-16 as well as its correlation with 99mTc-TRODAT-1 SPECT, its positive
predictive value (PPV), and negative predictive value (NPV).
Results: We identified a negative correlation between SS-16 and DAT SPECT (Kappa = 0.269, p = 0.004). By using the
99mTc-TRODAT-1 uptake results as the gold standard, the sensitivity and specificity of SS-16 was 56.8 and 37.5 %,
respectively. Furthermore, the negative and positive predictive values were calculated as 13.6 and 83.3 %, respectively.
Conclusions: SS-16 would not be used as a diagnostic tool for early stage PD patients. Negative results of SS-16 would
not exclude the diagnosis of PD. Further tests are needed for validation.
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Background
At least 50 % of nigrostriatal neurons have already been
lost at the time of clinical diagnosis for Parkinson’s dis-
ease (PD), a diagnosis which significantly relies on the
identification of classical motor symptoms. An early and
precise diagnosis of PD is critical since early treatment
with neuroprotective agents before most substantial
neuronal loss has occurred is believed to be beneficial
which could potentially slow or prevent the development
of PD symptoms.
As one of the most common non-motor symptoms, a
majority of PD patients are diagnosed with olfactory im-
pairment, which may even appear before the develop-
ment of motor symptoms. Therefore, analysis of
olfaction may be a useful diagnostic tool for PD. There
are two main olfactory tests available that can readily be
utilized in PD patients, the University of Pennsylvania
40-item smell identification test (UPSIT-40) and the
“Sniffin’ Sticks” 16-item identification test SS-16 [1].
Tests of odor identification might help differentiate PD
patients from healthy controls and have many advan-
tages, including: low cost, ease of administration and
rapid results. Therefore, olfactory tests are suited for
routine use in daily clinical practice and are currently
utilized in Europe. Our previous study indicated that SS-
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16 act as a valid instrument for olfactory assessment in
Chinese PD patients, and hyposmia may correlate with
autonomic dysfunction in patients with PD [2].
In recent years, studies have demonstrated that a
steady degradation of striatal uptake was observed as a
function of clinical duration after an estimated preclin-
ical duration of eleven years prior to PD symptom onset
[3]. Several different diagnostic tools have been evalu-
ated for their ability to detect nigrostriatal cell loss. The
most widely used tests are dopamine transporter single-
photon emission computed tomography (DAT SPECT),
[18 F]DOPA positron emission tomography (PET), and
transcranial sonography (TCS) [4]. A recent systematic
review indicated that sensitivity and specificity of DAT
SPECT imaging to detect nigrostriatal cell loss were
98 %, and it seems to be accurate in detecting nigrostria-
tal cell loss in patients with Parkinsonism [4]. SPECT-
based brain scans have become increasingly common in
routine PD diagnosis [2, 5, 6]. However, these scans are
expensive and there are still technical issues which can
lead to difficulties with interpretation in borderline
cases. In this study, using DAT SPECT results as the
clinical gold standard, we assessed the diagnostic accur-
acy of SS-16 on 52 patients diagnosed with PD based on
clinical features in their early stage. Furthermore, this
enabled us to also assess the ability of hyposmia defined
by a SS-16 score to predict a DAT deficit.
Methods
Participants
A total of 52 PD patients were recruited in this study by
consecutive referral at the movement disorders clinic in
the Department of Neurology, Ruijin Hospital affiliated
to Shanghai Jiao Tong University School of Medicine.
Two senior movement disorders specialists clinically
identified all patients in this study according to the
United Kingdom Parkinson’s Disease Society Brain Bank
criteria. Patients with possible olfactory dysfunction
secondary to other causes, such as nose surgery,
chronic sinusitis, acute upper respiratory tract infection
and other central nervous system diseases were ex-
cluded. Moreover, illiterate individuals were excluded
from this study. All patients underwent the Chinese
equivalent of the Mini Mental State Examination. We
excluded participants with scores less than 20 for indi-
viduals that received 6 years or less of primary school
education and participants with scores less than 24 for
individuals that received more than 6 years of school-
ing. All subjects read and signed an informed consent
prior to participation in the study. This study was
approved by the Ethics Committee of Ruijin Hospital




99mTc-TRODAT-1 SPECT was performed as described
in our previous study [7]. Briefly,two hours after intra-
venous injection of 99mTc-TRODAT-1, prepared from a
pre-formulated kit provided by Jiangsu Nuclear Medi-
cine Institute (WuXi city, China), 99mTc-TRODAT-1 up-
take was assessed by SPECT imaging. Images were
acquired via a double-headed gamma camera (Simens,
Symbia T16), with a 140 ± 14 keV energy window. Ac-
quisition time for the projection was 30s, with a 1.45
zoom and 3 mm slice thickness at the level of the basal
ganglia. Regions of interest (ROIs) for 99mTc-TRODAT-1
uptake were established by MRI (1.5 T, Siemens,
Germany). Of note, if the average 99mTc-TRODAT-1 up-
take was less than 1.21 for the right side or 1.31 for the
left side, striatal uptake (a combination of putamen and
caudate uptake) of the alternative side was considered
pathological [8].
Odor identification test
Bilingual university graduate students translated the ori-
ginal SS-16 to Chinese (simplified) [9]. The content and
wording of the questionnaires were discussed with the
patients’ representatives and caregivers, as well as public
health experts. and the 16 odors in the original “Sniffin’
Stick” odor identification test were kept the same but al-
ternative descriptions were developed to accommodate
the Chinese population. For example, the descriptions
“pine tree” and “grapefruit” were replaced with the Man-
darin equivalent of “wood,” and “pomelo”, which are
common in mainland China and are similar odors. The
test was continuously revised until it was considered un-
ambiguous by the research committee. The odor sticks
were placed approximately 2 cm in front of the nose of
the subjects to smell for 3 s, and the subject was re-
quired to choose between four alternatives in a forced-
choice paradigm. The interval between tests of various
odors was about 30s. Each correct answer for each odor
received a score of 1; thus, the total score expressed as
the sum of correct responses ranged from 0 to 16. Sub-
jects with scores lower than 9.5 were defined as olfactory
impaired [2].
Statistical analysis
Statistical analysis was carried out using SPSS version
21. The diagnostic accuracy of SS-16 was determined by
comparing their results to the surrogate gold standard:
99mTc-TRODAT-1 scans. Diagnostic accuracy is defined
as the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV). Finally, we
used Kappa test to compare the consistency of the two
examinations. P values of less than 0.05 were considered
statistically significant.
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Results
Descriptives
The mean age of the 52 patients was 60.65 ± 7.82 years,
and the majority (32/52) were male. The mean course of
disease was 4.04 ± 3.54 years, and the mean Hoehn and
Yahr score was 1.63 ± 0.83. The average UPDRS III score
was 14.18 ± 11.23. The R/L-Striatal 99mTc-TRODAT-1
uptake was 0.81 ± 0.68. All recruited PD patients had the
16-item odor identification test from Sniffin’ Sticks
(SS-16), the score was 8.60 ± 3.16.
Accuracy of SS-16 in clinically diagnosed PD patients
For the complete overview of the results of the SS-16,
99mTc-TRODAT-1 SPECT in each subgroup of patients,
see Fig. 1.
In the 52 subjects (20 women, 32 men) who under-
went the 16-item odor identification test from Sniffin’
Sticks (SS-16), 30 subjects (57.69 %) had distinct hypos-
mia (SS-16 scores <9.5). Of the 30 patients, 25 (83.33 %)
had an abnormal 99mTc-TROD AT-1 uptake scan. 22 of
the 52 patients had normal olfactory dysfunction, while
only 3 had a normal 99mTc-TRODAT-1 uptake scan.
Taking 99mTc-TROD AT-1 uptake results as the gold
standard, the sensitivity of SS-16 was 56.8 % (25/(25 +
19)), and the specificity was 37.5 % (3/(5 + 3)).
Predictive value of SS-16 for the results of the DAT SPECT
scans
To estimate the predictive values of SS-16 for the early-
diagnosis of PD, all 52 patients were included in the ana-
lysis. In 28 patients (53.85 %), the result of the SS-16
was in accordance with the result of the 99mTc-TROD
AT-1 scan. The PPV of a positive SS-16 test result for an
abnormal scan was 83.3 % (25/30). However, the NPV of
a negative SS-16 test result for a normal scan was only
13.6 %(3/22). The false negative rate of SS-16 test result
for the DAT imaging result was 43.2 % (19/44). SS-16
and DAT-SPECT were both positive in 25 patients
(48.1 %), while 3 patients (5.8 %) had double negative
results. In summary, in 28 patients, the results of the
SS-16 test were in accordance with the results of the
DAT SPECT scan (Kappa test, Kappa = 0.269, P =0.004).
Therefore, the consistency was poor (see Table 1).
Discussions
Olfactory dysfunction is a prodromal symptom in PD
and can be found several years before the appearance of
motor signs. In addition, it develops independent of
treatment or age at onset. Olfactory tests, including
ethnically specific odors, were recommended by the
European Federation of Neurological Societies and the
Movement Disorder Society as screening tests for
pre-motor PD [10]. Moreover, the fact that α-
synuclein deposits are present in the olfactory bulb
and anterior olfactory nucleus at Braak stage I ex-
plains its high sensitivity in early PD [11]. A study
that correlated diffusion tensor imaging (DTI) with
olfactory deficit in early PD patients demonstrated
that the Fractional anisotropy (FA) values of White
Matter (WM) were significantly reduced in the early
PD group versus healthy controls [12].
Prior studies have demonstrated SS-16 reliability in
differentiating PD patients and healthy subjects in Asia
and Latin America [1, 2]. Furthermore, a previous study
suggested that the performance of Sniffin’ Sticks was
better than that of UPSIT, even among Children to
whom discriminating different smells is more perplexing
[7]. Thus, SS-16 showed capability in differentiating ol-
factory impairment in spite of the poor life experience of
different smells. In the present study we try to investi-
gate whether Sniffin’ Sticks hold the qualification to de-
tect early PD clinically with DAT SPECT as a gold
standard.
Fig. 1 The flowchart of categorization of subjects
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Previous studies focus on identifying the diagnostic
value of prodromal or early PD by combining smell tests
with imaging examinations [13, 14]. Nevertheless, the in-
vestigation of consistency between olfactory impairment
results and imaging diagnosis standards is lacking. In the
present study, we found that the correlation between
these two items is negative (Kappa = 0.269, p = 0.004).
Taking 99mTc-TROD AT-1 uptake results as the gold
standard, the sensitivity of SS-16 for DAT SPECT was
56.82 % with a false negative predictive value of 43.2 %.
The negative predictive value was 13.6 %, and the speci-
ficity was only 37.5 %, while the positive predictive value
was 83.3 %. The over misdiagnosis was reasonable to
some degree and a number of factors might contribute
to this outcome.
First, although olfactory impairment acts as a symp-
tom of PD originating from extranigral neuropatho-
logical change according to Braak staging of Parkinson’s
disease, hyposmia is prevalent in Parkinson’s disease
with the deficiency of smell test ranging from 73 to
90 %, indicating a minority of PD patients not suffering
from olfactory deficiency [15]. In a recent study, the
utilization of SS-16 was compared among different
countries with China included. The results suggested
that the scores of several items called “component1”
were significantly different across PD patients from dif-
ferent country groups because of culture, smell familiar-
ity and environmental variations [11, 16]. Our previous
study used the adapted SS-16 translational version
evaluation (mentioned in the methods) in Chinese pa-
tients, resulting in a sensitivity of 86 % and the specifi-
city of 81 % in discriminating PD patients from healthy
controls. Among the 110 patients, 66.4 % were identified
as having hyposmia. In addition, the cohort of 52 pa-
tients was in the early stage (Hoehn and Yahr score was
1.63 ± 0.83), thus, 57.7 % could be explained in the study
and may not affect the results [2]. Thus, a certain rate of
false negative and positive value exists in the particular
SS-16 test and among a certain number of Chinese
population. To that end, a larger sample size to evaluate
the SS-16 test is in urgently needed to demonstrate
stable scale characteristics.
Second, in the present study, the clinical PD diagnosis
fulfilled the established UK Parkinson’s Disease Society
Brain Bank clinical diagnostic criteria. The clinical symp-
toms of PD were assessed by movement disorder spe-
cialists. Nevertheless, some atypical parkinsonism related
disorders, such as MSA, essential tremor progressive
supranuclear palsy and cortico-basal degeneration, might
not be clearly discriminated from PD in the early disease
course. However, olfactory function among the above
diseases is impaired mildly and for monogenic PD, espe-
cially in recessive forms, the dysfunction is less serious
than in PD. Consequently, there is a tendency for false
negative predictive value elevation and with reduced
specificity.
Third, with regard to DAT-SPECT diagnosistic cap-
ability, M. Menendez-Gonzalez [17] concluded that false
negative values would become higher due to the quanti-
tative analysis of SPECT scans and the existence of
SWEDDs (scans without evidence of dopaminergic defi-
cits). In addition, in early PD, 15 % patients might show
normal brain scan results. The misdiagnosis could not
be excluded in the assessment.
The present study is the first to take DAT SPECT as
the gold standard to assess the correlation between SS-
16 scores and 99mTc-TROD AT-1 uptake results from
SPECT imaging in a Chinese population. The positive
predictive value against SPECT was 83.3 %. Our previ-
ous study compared TCS with SPECT, finding the posi-
tive predictive value to be 91.7 % which was not much
higher than SS-16 [8]. However, negative results of the
SS-16 test could not exclude the diagnosis of PD. And
there are some limitations in our study. For one thing,
healthy subjects were not enrolled in the study. In
addition, this study is limited by the small sample size of
52 patients, and larger samples are necessary in the fu-
ture to produce results more representative of the
population.
Conclusions
In conclusion, SS-16 is a non-invasive, low cost, rapid
and convenient procedure recommended to be used as a
clinical test in spite of the negative correlation with
dopamine uptake results reflected via DAT SPECT. SS-
16 would not be used as a diagnostic tool for early stage
PD patients as a negative SS-16 test result could not ex-
clude the diagnosis of PD.
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